- Home
- NXGL vs NCNA Comparison
NXGL vs NCNA Comparison
Compare NXGL & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | NCNA |
|---|---|---|
| Founded | 1997 | 1997 |
| Country | United States | United Kingdom |
| Employees | 19 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 8.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | NXGL | NCNA |
|---|---|---|
| Price | $0.62 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 141.8K | 44.3K |
| Earning Date | 05-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.77 | N/A |
| Revenue Next Year | $46.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.03 |
| 52 Week High | $3.02 | $10.00 |
Technical Indicators
Market Signals| Indicator | NXGL | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 61.30 |
| Support Level | $0.58 | $2.07 |
| Resistance Level | $1.76 | $2.27 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 26.60 | 88.06 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.